| abstract |
In the novel piperidine and pyrrolidine derivatives (I) of the present invention, in the general formula (I), R 1 is unsubstituted or is halo, -A, -OA, -OH, -CN, -NO 2, phenyl, -O-SO 2 A and / or -O- SO2CF3 diphenyl substituted diphenyltitrile phenyl diphtheria; unsubstituted or substituted or unsubstituted 2 or 3 indoleyl moieties with Hal atom, -A, -O-A, -OH, and / or -CN; 1,4-benzodioxan-5 or -6-ylpiperidate; or 1- or 2-naphthylpiperidine; R2 is unsubstituted or phenyl or pyridinyl unsubstituted or unsubstituted with Hal atoms -A, -O-A, -OH, and / or -CN; R3 is hydrogen; -A, -O-A, phenyl, -NHR4, or -NR5R6, an unsubstituted or R4-unsubstituted or phenyl-pyridyl substituted with -A, -O-A, -OH, and / or -CN anthers; or cycloalkylpaste; R5 and R6 taken together are alkylene chainstones having 4, 5 or 6 carbon atoms; A is a straight or branched chain alkyltube moiety which may be substituted by fluorine and / or chlorine; or cycloalkylpaste; Hal is fluorine, chlorine, bromine or iodine; k and l are each independently 0 or 1; m is 0, 1 or 2; and n is 1 or 2; with the proviso that k is different from 1; and k is 0 if m is 2. The novel compounds and pharmaceutically acceptable salts thereof have 5-HT1A receptor antagonist activity and, on this basis, dietary disorders, learning disorder, stone-dependent memory disorders, They can be used for the elimination of delayed steam disturbances as well as for the steam blinding of obsessive-compulsive behavior. The new compounds also inhibit the re-uptake of 5-hydroxy-tryptamine. ŕ |